On June 26, Arcutis Biotherapeutics Inc. announced that ZORYVE (roflumilast) cream 0.15% received a strong recommendation in ...

Apogee Therapeutics, Inc.'s APG777 shows promising week-16 efficacy and dosing potential, targeting the AT market. Click for ...

AD and psoriasis were once thought to be opposites in terms of immune response, with AD linked to a Th2-dominant pathway and ...

The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...

Apogee Therapeutics (NASDAQ:APGE) stock fell on Monday despite the announcement that it met its main goal in part A of its ...

A focused update to AAD’s adult AD guidelines recommends tapinarof, roflumilast, lebrikizumab, and nemolizumab based on ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Apogee Therapeutics shares soared in premarket trading Monday after the company said it received positive trial data for its atopic dermatitis treatment. Shares traded 36% higher ahead of the morning ...

Apogee's APG777 showed a 71% drop in eczema severity and strong itch relief in a Phase 2 trial for atopic dermatitis. Part B ...

Spongiotic dermatitis describes skin inflammation that causes swelling, redness, and itching. It's most often associated with ...

Arcutis is financially strong, with over 30 months of cash runway. The atopic dermatitis market is large and shifting away ...

Intermittent treatment with pimecrolimus over 1 year significantly reverses corticosteroid-induced skin atrophy and ...